For the year ending 2026-01-02, EXEL had $265,114K increase in cash & cash equivalents over the period. $875,838K in free cash flow.
| Cash Flow | 2026-01-02 | 2025-01-03 | 2023-12-29 | 2022-12-30 |
|---|---|---|---|---|
| Revenues | 2,320,126 | - | - | - |
| Cost of goods sold | 83,697 | - | - | - |
| Drug discovery | 89,931 | - | - | - |
| Development | 567,843 | - | - | - |
| Selling, general and administrative | 446,536 | - | - | - |
| Other segment items | 260,126 | - | - | - |
| Interest income | 69,213 | - | - | - |
| Provision for income taxes | 158,636 | - | - | - |
| Net income | 782,570 | 521,267 | 207,765 | 182,282 |
| Depreciation and amortization | 29,055 | 28,803 | 25,717 | 20,875 |
| Impairment of long-lived assets | 0 | 64,391 | - | - |
| Stock-based compensation | 112,983 | 93,836 | 106,345 | 107,574 |
| Non-cash lease expense | 24,229 | 27,461 | 28,976 | 18,315 |
| Deferred taxes | -126,237 | 59,458 | 133,209 | 60,358 |
| Acquired in-process research and development technology | 11,999 | 50,750 | 128,500 | 107,250 |
| Other, net | 11,609 | 13,626 | 16,797 | 525 |
| Trade receivables, net | 21,398 | 27,950 | 22,623 | -66,849 |
| Inventory | -12,225 | -5,453 | 12,977 | 11,683 |
| Deferred revenue | - | - | -3,140 | -2,483 |
| Prepaid expenses and other assets | 133,771 | -31,079 | 29,824 | 28,259 |
| Accrued collaboration liabilities | 1,899 | -149 | 1,345 | -63,065 |
| Accounts payable and other liabilities | -50,152 | -21,886 | 53,246 | 25,842 |
| Net cash provided by operating activities | 884,267 | 699,971 | 333,324 | 362,614 |
| Purchases of marketable securities | 632,497 | 927,905 | - | - |
| Proceeds from maturities and sales of investments | - | - | 1,038,482 | 1,064,758 |
| Proceeds from maturities and sales of marketable securities | 1,022,866 | 877,307 | - | - |
| Purchases of property, equipment and other, net | 8,429 | 28,435 | 40,469 | 27,706 |
| Purchases of investments | - | - | 902,468 | 1,450,716 |
| Acquired in-process research and development technology | 31,499 | 37,750 | 122,500 | 110,750 |
| Net cash provided by (used in) investing activities | 350,441 | -116,783 | -26,955 | -524,414 |
| Payments for repurchases of common stock | 947,511 | 652,033 | 550,378 | - |
| Proceeds from issuance of common stock under the equity incentive plan and stock purchase plan | 49,137 | 61,850 | 33,448 | 23,886 |
| Taxes paid related to net share settlement of equity awards | 71,220 | 38,625 | 29,122 | 23,300 |
| Net cash used in financing activities | -969,594 | -628,808 | -546,052 | 586 |
| Net increase (decrease) in cash and cash equivalents | 265,114 | -45,620 | -239,683 | -161,214 |
| Cash and cash equivalents at beginning of period | 217,374 | - | - | - |
| Cash and cash equivalents at end of period | 482,488 | - | - | - |
EXELIXIS, INC. (EXEL)
EXELIXIS, INC. (EXEL)